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Abstract
Background: There is strong evidence demonstrating that activation of epidermal growth factor receptors (EGFRs) 
leads to tumor growth, progression, invasion and metastasis. Erlotinib and gefitinib, two EGFR-targeted agents, have 
been shown to be relevant drugs for lung cancer treatment. Recent studies demonstrate that lapatinib, a dual tyrosine 
kinase inhibitor of EGFR and HER-2 receptors, is clinically effective against HER-2-overexpressing metastatic breast 
cancer. In this report, we investigated the activity of lapatinib against non-small cell lung cancer (NSCLC).
Methods: We selected the lung cancer cell line A549, which harbors genomic amplification of EGFR and HER-2. 
Proliferation, cell cycle analysis, clonogenic assays, and signaling cascade analyses (by western blot) were performed in 
vitro. In vivo experiments with A549 cells xenotransplanted into nude mice treated with lapatinib (with or without 
radiotherapy) were also carried out.
Results: Lapatinib dramatically reduced cell proliferation (P < 0.0001), DNA synthesis (P < 0.006), and colony formation 
capacity (P < 0.0001) in A549 cells in vitro. Furthermore, lapatinib induced G1 cell cycle arrest (P < 0.0001) and apoptotic 
cell death (P < 0.0006) and reduced cyclin A and B1 levels, which are regulators of S and G2/M cell cycle stages, 
respectively. Stimulation of apoptosis in lapatinib-treated A549 cells was correlated with increased cleaved PARP, active 
caspase-3, and proapoptotic Bak-1 levels, and reduction in the antiapoptic IAP-2 and Bcl-xL protein levels. We also 
demonstrate that lapatinib altered EGFR/HER-2 signaling pathways reducing p-EGFR, p-HER-2, p-ERK1/2, p-AKT, c-Myc 
and PCNA levels. In vivo experiments revealed that A549 tumor-bearing mice treated with lapatinib had significantly 
less active tumors (as assessed by PET analysis) (P < 0.04) and smaller in size than controls. In addition, tumors from 
lapatinib-treated mice showed a dramatic reduction in angiogenesis (P < 0.0001).
Conclusion: Overall, these data suggest that lapatinib may be a clinically useful agent for the treatment of lung cancer.
Background
Several targeted therapies are commonly used today as
single agents or in combination with radiation or chemo-
therapeutic drugs for the treatment of solid tumors. Since
activation of epidermal growth factor receptor (EGFR)
promotes mechanisms leading to tumor growth and pro-
gression, EGFR-targeted agents are being widely
explored. In addition, some solid tumors, such as lung
cancer, exhibit EGFR gene amplification [1,2]. The most
clinically advanced EGFR tyrosine kinase inhibitors are
erlotinib (Tarceva) and gefitinib (Iressa). Iressa has been
shown to be highly effective in non-small-cell lung cancer
(NSCLC) patients with activating EGFR mutations [3].
Results with erlotinib in Phase III trials are more promis-
ing and the treatment of advanced or metastatic NSCLC
with erlotinib is now approved by the FDA [4]. Neverthe-
less, there remains an urgent need for the identification of
additional tyrosine kinase inhibitors that are effective
against lung cancer.
Novel drugs such as lapatinib are currently undergoing
clinical trials for the treatment of NSCLC, and other
tumors [4]. Lapatinib may have a therapeutic advantage
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over erlotinib because it acts as a dual inhibitor of EGFR
(or HER-1) and HER-2 (ErbB2) tyrosine kinases. In lung
adenocarcinomas, both EGFR and HER-2 are overex-
pressed and this is associated with poor prognosis [5]. In
addition, previous clinical trials have demonstrated that
both EGFR and HER-2 genes are amplified in lung cancer,
resulting in the overexpression of these proteins [1,2].
Such overexpression significantly correlates with gene
amplification [6]. Studies have shown that EGFR and
HER-2 protein overexpression is present in 43-89%, and
30-40% lung cancer specimens, respectively [2]. There-
f o r e ,  l u n g  t u m o r s  w i t h  h i g h  l e v e l s  o f  b o t h  E G F R  a n d
HER-2 may be appropriate for treatment with lapatinib.
The human NSCLC cell line A549 overexpresses both
EGFR and HER-2 and may be an excellent model for test-
ing the efficacy of lapatinib [7,8]. In fact, previous in vitro
studies have shown that A549 cells are sensitive to this
drug [9]. Other lung cancer cells, such as NCI-H358, and
Calu3 are also strongly inhibited by lapatinib [9]. In the
present work, we analyzed the in vitro and in vivo efficacy
of lapatinib on A549 lung cancer cells. Our results
showed that lapatinib decreased cell proliferation and
increased apoptosis in these cells in vitro. In A549-
injected nude mice, treatment with lapatinib significantly
reduced tumor activity and angiogenesis. Our data show
that lapatinib is an effective drug against NSCLC.
Methods
Cell culture
A549 bronchoalveolar carcinoma cells were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA) and maintained in complete medium,
consisting of RPMI 1640 growth medium (Invitrogen/
21875-034) with Glutamax®, supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 1% penicillin-
streptomycin (both antibiotics from Invitrogen). Cells
were grown at 37°C in a 5% CO2 atmosphere. Viable cells
were counted in a Neubauer chamber using the Trypan
Blue (Sigma-Aldrich, St Louis, MO) exclusion method.
Cell growth inhibition
Cells were seeded in 96-well plates at a density of 1000
cells/well. After 24 h to allow for attachment, cells were
treated with 0.05, 0.5 and 5 μM lapatinib (Tykerb®, Glaxo-
SmithKline) or left untreated (controls). Cell proliferation
was determined with the MTT Cell Proliferation Kit I
(Roche, Mannheim, Germany), according to the manu-
facturer's recommendations. Readings were done at 540/
690 nm in the SunRise ELISA plate reader (Tecan Austria
GmbH, Salzburg, Austria).
Clonogenic assay
A549 cells (50,000 per well) were plated (in triplicates)
into 6-well plates. After 24 h, cells were treated with 2 μM
lapatinib and detached with Trypsin-EDTA (Cambrex
Bio Science Verviers, Belgium) one day later. Cells were
then counted and 500 cells per 10 cm culture dishes were
re-seeded (in triplicates). After 12 days in culture, colo-
nies were fixed with 10% buffered formalin and stained
with 2% crystal violet. The number of colonies were
determined and normalized to the number of colonies in
controls.
Cell cycle analysis and apoptosis
After incubation with 2 μM lapatinib for 24 h, cells were
centrifuged at 1200 rpm for 5 min, fixed in 70% alcohol,
kept on ice for 1 h, centrifuged, and washed with PBS.
The samples were then resuspended in 500 μL PBS, and
10 μL RNAse A (10 mg/mL) was added and incubated at
37°C for 30 min. After addition of 10 μg/mL propidium
iodide (Sigma-Aldrich), the relative DNA content per cell
was obtained by measuring the fluorescence of the DNA.
The stained cells were detected by flow cytometry using a
FACSCalibur (BD Pharmingen, San Diego, CA) and the
subsequent analysis was performed with the CELLQuest
program. T o quantify apoptosis, cells were exposed to 2
or 5 μM lapatinib (for 24 h or 72 h), and active caspase-3
was measured with an apoptosis kit (FITC Active Cas-
pase-3 Apoptosis Kit, BD Pharmingen), according to man-
ufacturer's protocol.
Fluorescence in situ hybridization (FISH)
A549 cell suspension was spotted onto a glass slide and
air dried. Slides were incubated with protease solution
(50 mg/mL pepsin in 0.01 M HCl) at 37°C and fixed with
10% buffered paraformaldehyde. Samples were dehy-
drated by processing through a series ethanol concentra-
tions. Co-denaturation and hybridization of the probe
and cellular DNA were performed with a Hybridizer
(DAKO, Glostrup, Denmark), according to the manufac-
turer's protocol. HER-2/CEP17 FISH probes were
obtained from Vysis, Inc. (Dowers Grove, IL). Evaluation
of FISH signals was done by counting 100 nuclei and 100
metaphases and calculating the average of HER-2/CEP17
gene copy number per cell.
Western blot analysis
After treatment with 2 μM laptinib (or PBS as a control)
for 72 h, attached and floating A549 cells were collected
by centrifugation and lysed at 4°C in lysis buffer (10 mM
Tris-HCl, pH 7.4, 1% Triton X-100, 1% Na deoxycholate,
150 mM NaCl, 50 mM NaF, 5 mM EDTA, 0.1% SDS, 1
mM sodium vanadate). Extracts were aliquoted and
stored at -80°C for further Western blot analyses. Protein
concentrations were determined with the BCA Protein
Assay Kit (Pierce, Rockford, IL), resolved by SDS-PAGE,
and transferred to polyvinylidene difluoride membranes
(Bio-Rad, Hercules, CA). Membranes were blocked with
5% nonfat dry milk in TBS-Tween (1× TBS: 0.05 M Tris-Diaz et al. BMC Cancer 2010, 10:188
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HCl, 0.5 M NaCl, pH 7.36; 0.1% Tween-20) and incubated
at the recommended dilution with antibodies specific for
PCNA (Dako), GAPDH (AbD Serotec, Kidlington,
Oxford, UK), phospho-EGFR, total EGFR, phospho-
HER-2, total HER-2, phospho-AKT, total AKT, cleaved
PARP (Asp 214), XIAP (all of the latter ones from Cell
Signaling Technology, Danvers, MA); c-Myc, cyclin B1,
cyclin A, cyclin D1, Mcl-1, IAP-1, IAP-2, survivin (all of
these antibodies from Santa Cruz Biotechnology, Santa
Cruz, CA); Bcl-xL (BD Pharmingen); and Bak-1 (NT;
Upstate, Charlottesville, VA). Membranes were then
incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody (goat anti-mouse IgG or
goat anti-rabbit IgG, Santa Cruz Biotechnology). Immu-
noblots were developed with the chemiluminescence
detection system Lumi-Light PLUS (Roche), exposed to
Amersham Hyperfilm™ MP (Amersham, GE Healthcare,
Buckinghamshire, UK) and developed with an AGFA
automated X-ray film processor.
A549 xenograft mouse model and treatment with lapatinib
Four week-old male athymic nude (nu/nu) mice (Harlan,
Barcelona, Spain) were used in the study and maintained
in SPF (Specific Pathogen Free) environment. Animals (n
= 5 per group) were inoculated subcutaneously in the left
leg (using a sterile 22-gauge needle) with 0.2 mL of Matri-
gel (BD Pharmingen) containing 1×107 A549 cells (1:1
volume Matrigel/A549 cells) under ketamine-xylazine
anesthesia. Mice were randomized into two groups: a)
treated with 100 mg/kg body weight lapatinib (Tykerb®,
GlaxoSmithKline) or b) controls (injected with vehicle).
Treatments by daily gavage were started one week after
cell injection. Tumor width (W) and length (L) were mea-
sured once a week with a caliper and the tumor volume
(V) was calculated according to the formula: V = 0.5 × W2
× L. All the animal experiments were performed in accor-
dance with the guidelines for the Animal Care Ethics
Commission of our institution (University of Navarra)
under an approved animal protocol.
Small animal PET analyses
At the end of treatment (week 4), the effect of lapatinib
on tumor activity was measured by positron emission
tomography (PET) with the radiotracer 18 fluorodeoxyg-
lucose (18F-FDG). Mice were fasted overnight but allowed
to drink water ad libitum. The following day, mice were
anesthetized with 2% isoflurane in 100% O2 gas and 18F-
FDG (10 MBq ± 2 in 80-100 μL) injected via the tail vein.
To avoid radiotracer uptake in the hindlimb muscle, 18F-
FDG uptake was performed under continuous anaesthe-
sia for 50 min. PET imaging was performed in a dedicated
small animal Philips Mosaic tomograph (Cleveland, OH),
with 2 mm resolution, 11.9 cm axial field of view (FOV)
and 12.8 cm transaxial FOV. Anesthetized mice were
placed horizontally on the PET scanner bed to perform a
static acquisition (sinogram) of 15 min. Images were
reconstructed using the 3D Ramla algorithm (a true 3D
reconstruction) with 2 iterations and a relaxation param-
eter of 0.024 into a 128×128 matrix with a 1 mm voxel
size applying dead time, decay, random and scattering
corrections. For the assessment of tumor 18F-FDG
uptake, all studies were exported and analysed using the
PMOD software (PMOD Technologies Ltd., Adliswil,
Switzerland). Regions of interest (ROIs) were drawn on
coronal 1-mm-thick small-animal PET images on consec-
utive slices including the entire tumor. Finally, maximum
standardized uptake value (SUV) was calculated for each
tumor using the formula SUV = [tissue activity concen-
tration (Bq/cm3)/injected dose (Bq)] × body weight (g).
Lapatinib plus irradiation combination in vivo study
To assess the activity of lapatinib on A549 cells in
response to irradiation, combination treatments (irradia-
tion+lapatinib) were performed in nude mice. A549
tumor-bearing mice received a total irradiation dose of
16Gy (8 Gy/dose administered the second and third week
after cell injection). For this experiment, mice were ran-
domized into two groups: 1) X-ray irradiated alone and 2)
the combination of lapatinib (100 mg/Kg) and irradiation
at the indicated dose. Irradiation was performed with a
Primus® Linear Accelerator (Siemens AG, Erlangen, Ger-
many) X-ray machine.
Quantification of the circulating endothelial progenitors 
(CEPs)
To quantify the content of circulating endothelial progen-
itors (CEPs) in lapatinib-treated A549 xenografts by flow
cytometry analysis, a volume of 100-200 μL peripheral
blood was pre-incubated for 30 min at 4°C with 200 μL
PBS-EDTA-BSA (phosphate 10 mM, 3% EDTA, 2%
bovine serum albumin pH 7.4). Subsequently, samples
were incubated in darkness for 30 min at 4°C with 7-
aminoactinomycin-D (7AAD, Sigma-Aldrich), FITC-con-
jugated anti-mouse CD45, APC-conjugated anti-mouse
CD117, and PE-conjugated anti-mouse Flk-1/KDR (the
latter ones from BD Pharmingen). Cells were plotted
according to forward scatter and side scatter profiles and
gated to include only mononuclear cell events and to
exclude cell doublets, platelets, dead cells/debris,
microparticles and high side scatter events. The number
of CEPs (CD45-CD117+VEGFR2+) were quantified and
expressed as percentage (number of CEPs per hundred
viable mononuclear cells).
Immunohistochemistry for CD31 and quantification of 
tumor angiogenesis
A549 lung cancer tissues were fixed in 10% buffered for-
malin, embedded in paraffin, and sectioned (5 μm inDiaz et al. BMC Cancer 2010, 10:188
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thickness). Slides were stained with H&E and Masson
Trichrome. For immunohistochemistry, slides were
deparaffinized, incubated for 30 min with 3% H2O2 in
methanol to quench the endogenous peroxidase activity
and hydrated through graded alcohols. Antigen retrieval
was carried out as follows: Slides were incubated with 50
μg/mL proteinase K for 30 min at 37°C and 20 min at
room temperature. Tissues were then incubated with goat
normal serum in buffer Tris- EDTA (TE) at 1:20 dilution
for 30 min at room temperature. The anti-CD31 mono-
clonal antibody (BD Pharmingen) was diluted 1:25 in TE
buffer and incubated overnight at 4°C. Slides were then
incubated for 30 min at room temperature with a second-
ary rabbit anti-rat antibody at 1:200 dilution in TE buffer.
Afterwards, slides were incubated for 30 min with the
EnVision™ anti-rabbit detection system (Dako). Peroxi-
dase activity was carried out with DAB (3,3'-diaminoben-
zidine, Dako). Finally, slides were counterstained with
hematoxylin, dehydrated, and mounted with DPX. For
quantifications, 30 random images (400×) per experi-
mental group were captured with a microscope (Leica,
Wetzlar, Germany) equipped with the Analysis™ software.
CD31-positive vessels were quantified with the Axiovi-
sion 4.6 software (Zeiss). Measurements are given as rela-
tive area occupied by CD31-positive vessels with respect
to the reference area.
Statistical analysis
Unpaired two-tailed Student's t test was used to analyze
comparisons between two groups. One-way ANOVA
with Newman-Keuls multiple comparison Test was used
to analyze vessel density data. Statistical differences were
considered significant when p < 0.05.
Results
HER-2 gene amplification in A549 cells
Previous studies have shown that A549 cells harbor EGFR
gene amplification [7], but the HER-2 status of these cells
was unknown. We determined whether the HER-2 gene
is also amplified in A549 cells. Using a DNA probe spe-
cific for HER-2 (red) and a DNA probe specific for the
centromere of chromosome 17 (green), genetic analysis
was carried out by Fluorescence in situ hybridization
(FISH). Results showed that 13% of A549 cells contained
normal copies of the HER-2 gene, as demonstrated by
two green and two red signals. However, 21% of the
nuclei exhibited HER-2 gene amplification as shown by
four red HER-2 signals and two green centromeric sig-
nals. Most of the A549 nuclei were tetrasomic (four cen-
tromeric signals of chromosome 17 and 4-5 copies of
HER-2); this accounted for 66% of all the nuclei of A549
cells. A representative picture of HER-2 FISH analysis is
shown in Fig 1. Metaphases of A549 chromosomes were
also analyzed confirming that the majority of cells exhib-
ited tetrasomy for chromosome 17. We therefore con-
clude that similar to EGFR, A549 exhibits HER-2 gene
amplification.
Laptinib inhibits A549 lung cancer cell growth
A549 cells treated with lapatinib (0.05, 0.5 and 5 μM) for
24 h showed a dose dependent decrease in cell prolifera-
tion compared to controls. After 72 h of exposure, a
strong reduction was observed (P < 0.0001) (Fig 2). For
further experiments, we chose a 2 μM concentration,
which produces 35% cell growth inhibition (Fig 3A). Clo-
nogenic assays revealed that, whereas untreated cells gave
rise to 305 ± 5 colonies, lapatinib-treated cells signifi-
Figure 1 FISH analysis showing 4 signals for HER-2 (red) and 4 sig-
nals for the chromosome 17 centromere (green) in A549 cells.
Figure 2 Cytotoxicity of lapatinib in A549 cells exposed to differ-
ent concentrations (0.05, 0.5 and 5 μM) of the drug, for 24 h and 
72 h. At the indicated time point, cell viability was measured by MTT, 
indicating that lapatinib significantly reduces A549 cell proliferation 
(**: P < 0.01; ***:P < 0.001).Diaz et al. BMC Cancer 2010, 10:188
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cantly reduced the colony formation ability to 127 ± 8 (P
< 0.0001) (Fig 3B). These data show that Lapatinib inhib-
its the growth of the A549 lung cancer cell line.
Lapatinib alters the cell cycle in A549 cells
The antiproliferative activity of lapatinib in A549 cells
prompted us to analyze the effect on the cell cycle. A549
cells treated with 2 μM lapatinib for 24 h resulted in a sig-
nificant reduction in the S and G2/M phases (P < 0.006
and P < 0.0001, respectively). 17.0 ± 0.3% (mean ± SD) of
untreated cells were in S phase and 22.1 ± 0.4% in G2/M
phase, whereas 15.4 ± 0.4% in S phase and 17.1 ± 0.4% in
G2/M phase were found for cells exposed to lapatinib (Fig
4A). In keeping with these results, the levels of cyclins A
and B1, regulators of S and G2/M stages, respectively,
were lower in lapatinib-treated cells compared to controls
(Fig 4B). Treatment with lapatinib resulted in a significant
increase in the percentage of cells in the G1 phase (from
58.9 ± 0.3% to 63.9 ± 0.2%; P < 0.0001). Basal levels of
cyclin D1 (a regulator of the G1 phase) were very low in
A549 cells, but no changes seemed to be produced upon
lapatinib treatment (Fig 4B). Finally, administration of
lapatinib caused a significant increase (3-fold) in the
subG1 phase (suggestive of apoptosis): From 1.13 ± 0.08%
to 3.37 ± 0.3%; P  < 0.0006. Taken together, these data
show that lapatinib causes cell cycle alterations with G1
arrest, DNA synthesis reduction and cell death induction,
in A549 lung cancer cells.
Alteration of the EGFR/HER-2 receptors and downstream 
signaling cascades by lapatinib results in apoptosis 
induction in A549 cells
To verify alterations in the EGFR/HER-2 receptors and
downstream signaling pathways, we analyzed protein lev-
els of p-EGFR, EGFR, p-HER-2, HER-2, p-ERK1/2, ERK1/
2, p-AKT, AKT, c-myc, and PCNA (Fig 5A). As expected,
lapatinib reduced levels of p-EGFR, p-HER-2, and p-
ERK1/2 in A549 cells. Since studies in other tumor types
have shown that the AKT pathway may also be perturbed
by lapatinib, we analyzed p-AKT levels before and after
treatment. Indeed, reduced levels in the phosphorylated
form, but no changes in total AKT were found, after
exposure to the drug. In addition, c-Myc and PCNA lev-
els were also reduced (Fig 5A). Treatment with lapatinib
resulted in an increase in cleaved PARP, which is a sub-
strate for activated caspases (Fig 5B). Lapatinib reduced
the levels of the two antiapoptotic proteins IAP-2 and
Bcl-xL, and increased the levels of the proapoptotic pro-
tein Bak-1. However, no changes were found in the anti-
apoptotic proteins Mcl-1, IAP-1, XIAP, survivin and the
proapoptotic protein Bax (Fig 5B). To confirm quantita-
tively the apoptotic induction, active caspase-3 was mea-
sured by flow cytometry. The following results were
obtained: Twenty-four hours after treatment, 4.63 ±
0.77% and 4.59 ± 0.42% of the cells were positive when 2
μM or 5 μM were used (respectively), compared with 3.92
Figure 4 Cell cycle study of A549 cells treated with lapatinib. A. 
Lapatinib significantly alters cell cycle phases (G1 arrest and DNA syn-
thesis reduction) analyzed by flow cytometry after propidium iodide 
staining (**: P < 0.01; ***: P < 0.001); B. Western blot showing the effect 
of lapatinib on the expression of the cell cycle regulators cyclins A, B1 
and D1. In treated cells, the lower levels of cyclins A and B1, regulators 
of S and G2/M stages, respectively, corroborated the results described 
by cytometry. Levels of cyclin D1, a regulator of the G1 phase, were 
very low and remained unchanged upon treatment.
Figure 3 Analysis of cell survival after 2 μM lapatinib treatment. 
A. A549 cells exposed to 2 μM lapatinib for 24 h exhibited a reduced 
cell growth proliferation (P < 0.001); B. After 10 days of exposure to la-
patinib, the number of colonies was dramatically abrogated (***: P < 
0.0001).Diaz et al. BMC Cancer 2010, 10:188
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± 0.22% for controls. Seventy two hours after the admin-
istration of the drug, the following values were found:
8.00 ± 0.18% for 2 μM, and 9.07 ± 0.22% for 5 μM, in com-
parison to 5.21 ± 0.18% for untreated control cells. These
results indicate a proapoptotic effect induced in A549
lung cancer cells upon lapatinib treatment.
Lapatinib activity in lung tumor xenografts
After 4 weeks of daily treatment of A549 tumor-bearing
mice with lapatinib, tumor growth was reduced by more
than 57% (on average) compared to controls (433 mm3
versus 1015 mm3), although no statistical differences
were reached, probably due to high variability of tumor
growth in the control group (Fig 6A). However, measure-
ment of tumor metabolism (18F-FDG uptake) with small
animal PET analysis showed a significant reduction (P =
0.037) in mice treated with lapatinib compared to con-
trols. SUV -- standardized uptake value (mean ± SEM)--
for controls was 0.94 ± 0.17, whereas the value for lapa-
tinib-treated mice was 0.32 ± 0.20 (Fig 6B).
Previous studies have shown that EGFR or HER-2 inhi-
bition may potentiate the effect of radiation therapy [10].
We were particularly interested in testing if lapatinib can
enhance the effect of radiotherapy in the A549 xenograft
lung cancer model. Radiotherapy treatment (16 Gy) in
combination with lapatinib reduced tumor volume with
respect to radiotherapy alone by 48% (353 mm3 versus
671 mm3) (Fig 7); however, no statistical differences were
observed. Analysis of 18F-FDG uptake in tumors by PET
showed that the metabolic activities in radiotherapy-
treated and radiotherapy plus lapatinib-treated animals
were similar (SUV = 0.56 ± 0.16 and 0.40 ± 0.13, respec-
tively) (data not shown). Therefore, in the A549 xenograft
lung cancer model, lapatinib does not enhance signifi-
cantly the effect of radiotherapy.
Lapatinib impairs angiogenesis and reduces circulating 
endothelial progenitors (CEPs) in A549 tumor-bearing mice
Since inhibition of EGFR and HER-2 has been shown to
reduce angiogenesis through an indirect effect on VEGF
production [11,12], we evaluated whether lapatinib inter-
feres with tumor angiogenesis in the A549 model in vivo.
Tumor angiogenesis (vessel density) was estimated by
analyzing CD31-stained tumor sections. Lapatinib dra-
matically reduced vessel density compared to controls
(0.59 ± 0.13 for lapatinib versus 4.6 ± 0.84 for controls; P
< 0.0001) (Fig 8A and 8B). Inhibition of angiogenesis was
a lso obse rved i n irra dia t ed m ic e  t r ea t ed wit h la pa ti nib
compared to mice exposed to radiotherapy alone (0.75 ±
0.18 for lapatinib versus 3.39 ± 0.39 for radiotherapy; P <
0.01) or compared with the untreated controls (P  <
0.0001) (Fig 8A and 8B). These results show that inhibi-
tion of angiogenesis may be an important mechanism in
vivo elicited by Lapatinib.
We were further interested in elucidating the contribu-
tion of circulating endothelial progenitor cells (CEPs) to
tumor angiogenesis. For this purpose, CEPs were mea-
sured in A549 tumor-bearing mice by flow cytometry
from the peripheral blood. Although not statistically dif-
ferent, lapatinib treated-mice reduced the number of
CEPs compared to untreated control mice (P = 0.584) (Fig
8C). In contrast, when mice were irradiated, the number
of CEPs increased (P = 0.197) (Fig 8C) similar to what was
previously described [13,14]. However, the combined
treatment (radiation plus lapatinib) produced a signifi-
cant reduction in the number of CEPs with respect to
radiation alone (P = 0.0167) (Fig 8C). These results rein-
force the idea that lapatinib impairs angiogenesis and
reduces the number of CEPs in A549 lung tumor-bearing
mice.
Discussion
Although progress has been made in the management of
advanced lung cancer, many challenges still remain. Che-
motherapy is the primary treatment for advanced NSCLC
patients. However, recent results suggest that no signifi-
cant improvement in survival is likely to occur in those
patients [15-17]. The overexpression of EGFR and HER-2,
which has been observed in a significant number of lung
cancer patients, offers an opportunity to block these
tyrosine kinase receptors with targeted drugs [2,18]. The
EGFR tyrosine kinase inhibitors erlotinib and gefitinib
were approved by the US Food and Drug Administration
(FDA) for the treatment of NSCLC. Although in random-
Figure 5 Intracellular signaling changes induced by lapatinib in 
A549 cells, analyzed by western blot. A. Immunoblots showing de-
creased levels of p-EGFR and p-HER-2 after stimulation with 100 ng/ml 
EGF and treatment with lapatinib. Downstream targets p-AKT, p-ERK1/
2, c-Myc and PCNA were also reduced upon exposure to the drug. B. 
After lapatinib treatment, the proapoptotic protein Bak-1 was in-
creased, the levels of the antiapoptotic proteins IAP-2 and Bcl-xL were 
reduced, and PARP was cleaved, thus demonstrating that the apoptot-
ic pathway is switched on by this drug in A549 lung cancer cells.Diaz et al. BMC Cancer 2010, 10:188
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ized phase III clinical trials gefitinib was not associated
with significant improvement in survival [19], its use has
been proven clinically effective for patients with activat-
ing EGFR mutations [3]. Lapatinib is a novel dual EGFR
and HER-2 tyrosine kinase inhibitor that is now approved
by the FDA for treatment of metastatic breast cancers
with overexpression of HER-2 receptors [20-22].
We used the A549 cell line model of NSCLC, which
expresses EGFR and HER-2, to test the preclinical effi-
cacy of lapatinib against lung cancer. Our results show
that lapatinib inhibits the growth and increases apoptosis
in these cells in vitro. More importantly, lapatinib inhibits
A549 tumor activity and angiogenesis in a xenograft
mouse model.
We have shown by FISH analysis that the HER-2 gene is
amplified in A549 cells. This is consistent with previous
studies that reported increased EGFR gene copy number
in lung tumours [1,2]. Prediction of DNA alterations
(gains or losses) to diverse genomic regions (chromosome
7, 11, 17 or 20 amplification and chromosomes 1, 2 or 9
deletions) in A549 cells have been recently associated
with sensitivity to lapatinib [7]. Interestingly, in A549
cells, chromosomal gains were predicted in the region
17q12, where the HER-2 gene is located [7]. The A549
cell line might therefore constitute an appropriate pre-
clinical model for testing the efficacy of lapatinib against
NSCLC.
We demonstrate in this model that lapatinib-mediated
blockade of both EGFR and HER-2 phosphorylation
causes downstream signaling alteration upon drug
administration. Similar to other EGFR inhibitors, such as
erlotinib, lapatinib inhibited cell growth of A549 cells,
and increased the proportion of cells in the G1 phase,
while decreased those in the S and G2/M phases [23]. A
possible reason for this cell cycle effect is the decrease in
the protein levels of cyclins A and B1, which are regula-
tors of S and G2/M phases, respectively. Lapatinib-
induced inhibition of cyclins A and B1 likely slows down
progression through the S and G2/M cell cycle phases,
contrasting with the result showing no change in cyclin
Figure 6 In vivo tumor growth assays. A. After tumor implantation into immunocompromised nude mice, animals were treated with lapatinib for 
four weeks at the indicated concentration. Tumor volumes in treated mice were smaller than those found in controls; B. Lapatinib significantly re-
duced tumor metabolism (P = 0.037), which was shown by the standardized glucose uptake values (SUV) measured with micro-PET.
Figure 7 In vivo effect of radiotherapy alone or in combination 
with lapatinib, in A549 tumor-bearing mice. Lapatinib reduced 
modestly tumor growth in irradiated animals compared to only irradi-
ated mice.Diaz et al. BMC Cancer 2010, 10:188
http://www.biomedcentral.com/1471-2407/10/188
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D1, a mediator of the G1 phase. This very same phenom-
enon has been observed with erlotinib [23].
We found that lapatinib blocks ERK1/2 phophorylation
in A549 lung cells, as previously described in lapatinib-
treated breast cancer cells [24]. Furthermore, p-ERK1/2
downregulation is followed by a downstream reduction of
c-Myc, which might contribute to the aforementioned G1
arrest. A recent work also demonstrated that c-Myc is a
target of lapatinib in gastric cancer cell lines [25]. In addi-
tion, these data are consistent with other reports demon-
strating that cyclin A is critical for c-Myc-modulated cell
cycle progression [26]. Therefore, lapatinib inhibition of
cyclin A may subsequently abrogate c-Myc and, in turn,
induce G1 phase arrest in A549 cells.
An important feature of anti-cancer agents is the ability
to trigger apoptotic cell death. Our results show that
treatment of A549 cells with lapatinib causes apoptosis,
as determined by an elevated proportion of cells in the
sub-G1 cell cycle phase, and increased cleaved PARP and
active caspase-3. Moreover, lapatinib decreased levels of
the anti-apoptotic proteins Bcl-xL and IAP-2. Bcl-xL is a
member of the Bcl-2 family that acts on the mitochon-
drial membrane to prevent release of caspase activators
such as cytochrome-C [27]. Overexpression of inhibitor
of apoptosis (IAP) family members (IAP-2 among them)
can also inhibit caspase activation, block apoptosis, and
increase drug resistance [28]. Therefore, the ability of lap-
atinib to reduce the levels of Bcl-xL and IAP-2 should
increase mitochondria outer membrane permeabilization
(MOMP), release cytochrome-C, and induce apoptosis.
Results presented here also show increased Bak-1 (a
proapoptotic member of the Bcl-2 family) levels, which
are required along with Bax to increase MOMP and
apoptosis. The correlation between lapatinib-induced cell
death, Bak activation and Bcl-xL downregulation has
been described as well in colon cancer cells [29].
The growth-inhibitory effects of lapatinib were also
evaluated in vivo. In the A549 xenograft model, this drug
reduced tumor growth, and glucose uptake (indicating
decreased metabolism and proliferative activity of tumor
Figure 8 Lapatinib alters angiogenesis and the number of circulating endothelial progenitors (CEPs) in mice xenotransplanted with A549 
tumor cells. A. Representative images of CD31-stained tumors from controls, lapatinib-treated, radiotherapy-treated and radiotherapy plus lapatinib-
treated mice. B. Lapatinib dramatically reduced the CD31-positive area in the tumors (*: P < 0.05; **: P < 0.01; ***: P < 0.001); C. Quantification of CEPs 
in A549 tumor-bearing mice by flow cytometry from the peripheral blood. Lapatinib tended to reduce the number of CEPs compared to controls. 
Interestingly, it significantly diminished the number of CEPs (P = 0.0167) that were increased after radiotherapy treatment.Diaz et al. BMC Cancer 2010, 10:188
http://www.biomedcentral.com/1471-2407/10/188
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cells). PET analysis has also been used in NSCLC patients
to monitor the response to the EGFR tyrosine kinase
inhibitor gefitinib [30]. In vivo experiments using lapa-
tinib in combination with radiotherapy showed no thera-
peutical benefit as compared to the use of each therapy
alone in our study. Therefore, at least in these experimen-
tal settings, lapatinib does not enhance the therapeutic
effect of radiotherapy. Randomized trials using lapatinib
were recently initiated in patients with locally advanced
s q u a m o u s  c e l l  c a r c i n o m a  o f  h e a d  a n d  n e c k  [ 1 0 ]  a n d
NSCLC [4]. Results from these studies and from other
preclinical models will determine whether the use of lap-
atinib alone or in combination with other therapeutical
agents may result in clinical benefit.
In vivo preclinical experiments using EGFR and VEGFR
inhibitors in colon cancer models reported several
important findings: First, both receptors were present in
tumor-associated mouse endothelial cells; and second,
targeting both receptors with the tyrosine kinase inhibi-
tor AEE788 reduced tumor growth and caused apoptosis
in both tumor and endothelial cells [31]. We have found
in the present study that treatment with lapatinib
decreases dramatically tumor angiogenesis (by >80%) as
compared to controls. This result suggest that blockade
of angiogenesis may be one critical in vivo mechanism
elicited by lapatinib. It is possible that inhibition of EGFR
downstream signaling reduces the expression of angio-
genic factors (such as VEGF, IL-8, etc.) through indirect
mechanisms. Interestingly, Olaussen et al. [32] have
recently demonstrated that lapatinib inhibits VEGFR1
phosphorylation by >70% in A549 cells. Although such an
effect has not been shown in endothelial cells, one could
assume that VEGFR1 phosphorylation blockade would
have a direct antiangiogenic effect. These issues should
be addressed in future studies.
Both peritumoral vessels and circulating bone-marrow-
derived endothelial progenitors (CEPs) contribute to
tumor angiogenesis [33]. In addition, CEPs are signifi-
cantly increased in NSCLC patients and are associated
with poor prognosis [34]. Our results show that lapatinib
reduces modestly the number of CEPs. Radiotherapy
caused an increase in CEPs in our in vivo model, similar
to that previously described in response to stress or ther-
apy, including radiation [13,14,35-37]. Interestingly, after
tumor irradiation and lapatinib administration, the num-
ber of CEPs was significantly reduced. Therefore, a
potential mechanistic function of lapatinib could be the
inhibition of endothelial cell recruitment to the tumor.
Conclusion
Our results show that lapatinib has antitumor activity in
vitro and in vivo against lung cancer, but does not act as
an enhancer of radiotherapy. Further studies will be
required to assess whether lapatinib alone or in combina-
tion with chemotherapy may be clinically relevant to treat
human lung cancer.
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